国际中轴型脊柱关节炎地图(IMAS):来自全球27个国家5557例患者视角的结果
IMAS是一项由ASIF、塞维利亚大学、诺华制药公司合作并由科学委员会指导的全球倡议,通过2017—2022年在线横断面调查收集欧洲、亚洲、北美、拉丁美洲和非洲未选择的中轴型脊柱关节炎患者信息。5557例患者平均年龄43.9±12.8岁,55.4%为女性,平均诊断延迟7.4±9.0年(中位数4.0),75.0%疾病活动(BASDAI≥4),59.4%心理健康状况差(GHQ-12≥3)。结论指出全球中轴型脊柱关节炎患者存在未满足需求、诊断延迟长和疾病负担高。
要点
- 5557例中轴型脊柱关节炎患者中75.0%疾病活动(BASDAI≥4),59.4%心理健康状况差(GHQ-12≥3)。
- 平均诊断延迟7.4±9.0年(中位数4.0),平均症状持续时间17.1±13.3年。
- 患者最大恐惧为疾病进展(55.9%),最大希望为能够缓解疼痛(54.2%)。
核心结论
- IMAS展示了全球中轴型脊柱关节炎患者的概况,突出全球范围内未满足的需求、诊断延迟时间长和疾病负担高。
- 该全球信息将使更详细的调查成为可能,以获取关于全球患者关心的关键问题的证据,从而改善其照护和生活质量。
研究设计与样本
- IMAS是由国际中轴型脊柱关节炎联盟(ASIF)、塞维利亚大学、诺华制药公司合作并由科学委员会指导的全球倡议。
- 通过2017—2022年在线横断面调查收集来自欧洲、亚洲、北美、拉丁美洲和非洲的未选择的中轴型脊柱关节炎患者信息。
- 问卷包含超过120个条目,共5557例患者参与。
主要发现
- 患者平均年龄43.9±12.8岁,55.4%为女性,46.2%有大学教育,51.0%在职。
- 平均诊断延迟7.4±9.0年(中位数4.0),平均症状持续时间17.1±13.3年。
- 75.0%患者疾病活动(Bath强直性脊柱炎疾病活动指数≥4),59.4%报告心理健康状况差(12项一般健康问卷≥3)。
- 调查前一年内,患者就诊全科医生4.6次、风湿科医生3.6次。
- 78.6%曾使用非甾体抗炎药,48.8%使用生物改善病情抗风湿药,43.6%使用传统合成改善病情抗风湿药;患者最大恐惧为疾病进展(55.9%),最大希望为能够缓解疼痛(54.2%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The International Map of Axial Spondyloarthritis (IMAS) is a global initiative aimed to assess the impact and burden of axial spondyloarthritis (axSpA) and identify the unmet needs from the patient's perspective. METHOD: IMAS is a collaboration between the Axial Spondyloarthritis International Federation (ASIF), the University of Seville, Novartis Pharma AG and steered by a scientific committee. IMAS collected information through an online cross-sectional survey (2017-2022) from unselected patients with axSpA from Europe, Asia, North America, Latin America and Africa who completed a comprehensive questionnaire containing over 120 items. RESULTS: 5557 patients with axSpA participated in IMAS. Mean age was 43.9 ±12.8 years, 55.4% were female, 46.2% had a university education and 51.0% were employed. The mean diagnostic delay was 7.4 ±9.0 years (median: 4.0), and the mean symptom duration was 17.1 ±13.3 years. 75.0% of patients had active disease (Bath Ankylosing Spondylitis Disease Activity Index ≥4), and 59.4% reported poor mental health (12-item General Health Questionnaire ≥3). In the year before the survey, patients had visited primary care physicians 4.6 times and the rheumatologist 3.6 times. 78.6% had taken non-steroidal anti-inflammatory drug ever, 48.8% biological disease-modifying antirheumatic drugs and 43.6% conventional synthetic disease-modifying antirheumatic drugs. Patients's greatest fear was disease progression (55.9%), while the greatest hope was to be able to relieve pain (54.2%). CONCLUSIONS: IMAS shows the global profile of patients with axSpA, highlighting unmet needs, lengthy delays in diagnosis and high burden of disease in patients with axSpA worldwide. This global information will enable more detailed investigations to obtain evidence on the critical issues that matter to patients around the world to improve their care and quality of life.
引用
- Garrido-Cumbrera M, Poddubnyy D, Sommerfleck F, et al. International Map of Axial Spondyloarthritis (IMAS): results from the perspective of 5557 patients from 27 countries around the globe. RMD Open. 2024. PMID: 38851236. doi:10.1136/rmdopen-2023-003504
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。